Belén Garijo, Chief Executive Officer: “Sanofi achieved another strong quarter with double-digit sales growth of 14.3%, mainly driven by our new medicines and Dupixent. Business EPS increased by 19.6%, driven by cost discipline. The pipeline milestones included two regulatory approvals, one…
Q3 2026: double-digit growth in sales and business EPS
FY 2026: guidance upgraded
October 30, 2026
Q3 sales growth of 14.3% at CER1 and business earnings per share (EPS)2 of €3.55
Pharma launches sales increased by 31.4%, reaching €1.4 billion, driven by ALTUVIIIO, Ayvakit, and Rezurock
Dupixent sales increased by 34.8% to €5.7 billion, above €5 billion per quarter for the second time
Vaccines sales decreased by 6.6% to €3.2 billion, impacted by the anticipated phasing in respiratory prevention
Research and Development expenses reached €1.8 billion, broadly stable
Selling and general expenses reached €2.3 billion, down by 0.9%, reflecting cost discipline
Business EPS was €3.55, up by 19.6% at CER; 22.0% at actual exchange rates; IFRS EPS €2.52
Pipeline update
Two regulatory approvals; in rare diseases and vaccines
One regulatory submission acceptance and two regulatory designations (priority review and PRIME)
Guidance upgraded
2026 guidance is upgraded: sales are expected to grow by a low-teens percentage at CER. Business EPS at CER is expected to grow by a mid-teens percentage.3
Belén Garijo, Chief Executive Officer: “Sanofi achieved another strong quarter with double-digit sales growth of 14.3%, mainly driven by our new medicines and Dupixent. Business EPS increased by 19.6%, driven by cost discipline. The pipeline milestones included two regulatory approvals, one regulatory submission, and two additional regulatory designations. Our strong commercial and financial momentum to date leads us to raise our 2026 guidance: sales growth is now expected at a low-teens percentage and business EPS growth at a mid-teens percentage, underscoring our sustainable, profitable growth. In the third quarter, we accelerated Sanofi’s transformation by expanding our long-standing alliance with Regeneron, which opens up further opportunities in immunology. We also continued to simplify our portfolio through a partnership with Cheplapharm covering a number of legacy medicines4.
We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organisation is focused on managing Sanofi’s post-Dupixent trajectory over the next decade. Our priority is to protect earnings through Dupixent’s loss of exclusivity. We have already begun taking action to improve R&D productivity. Business development and M&A will be critical to complement this transformation. We remain committed to our long-term capital allocation policy, including our progressive dividend.”
Q3 2026 Change Change at CER YTD 2026 Change Change at CER
Net sales €14,444m +16.2% +14.3% €36,550m +13.1% +15.2%
IFRS net income €3,021m +7.8% — €4,979m -42.2% —
IFRS EPS €2.52 +9.6% — €4.15 -41.1% —
Free cash flow5 €3,269m +9.2% — €6,993m +28.3% —
Business operating income €5,430m +22.2% +19.7% €11,688m +19.2% +21.1%
Business net income €4,255m +20.0% +17.6% €9,020m +17.2% +19.1%
Business EPS €3.55 +22.0% +19.6% €7.52 +19.4% +21.3%
Press Release
SANOFI PRESS RELEASE Q3 2026 1
1 Changes in net sales are at constant exchange rates (CER) unless otherwise stated (see definition in Appendix 8). 2 To facilitate an understanding of operational performance, Sanofi comments on business operating income, business net income, and business EPS (bEPS), which are non-IFRS financial measures (see definitions in Appendix 8). The IFRS consolidated income statement is in Appendix 3, and a reconciliation of IFRS net income to business net income is in Appendix 4.
3 Applying October 2026 average currency exchange rates, currency impacts are estimated at c.-1% on sales and at c.-1% on business EPS. 4 Subject to information and consultation procedures with employee representatives, regulatory approvals, and customary closing conditions. 5 Free cash flow is a non-IFRS financial measure (see definition in Appendix 8).
Q3 and YTD 2026 summary
A conference call and webcast for investors and analysts will begin at 13:30 CET with details on sanofi.com, including the slides. The performance shown in this press release covers the three-month period to September 30, 2026 (Q3 2026) and the ninemonth period to September 30, 2026 (the year-to-date (YTD) 2026) compared to the three-month period to September 30, 2025 (Q3 2025) and the nine-month period to September 30, 2025 (YTD 2025) respectively. All percentage changes in sales in this press release are at CER, unless otherwise stated.
In Q3 2026, sales were €14,444 million and increased by 14.3%. Exchange rate movements had a positive effect of 1.9 percentage points (pp); therefore, at actual exchange rates, sales increased by 16.2%. The divestments of medicines/portfolio streamlining had a negative impact of 0.4pp on sales growth. In YTD 2026, sales were €36,550 million and increased by 15.2%. Exchange rate movements had a negative effect of 2.1pp; therefore, at actual exchange rates, sales increased by 13.1%. The divestments of medicines/portfolio streamlining had a negative impact of 0.4pp on sales growth.
Sales by geography
Net sales
(€ million) Q3 2026 Change at CER YTD 2026 Change at CER
United States (US) 8,603 +23.9% 20,236 +27.4%
Europe 2,579 -0.9% 6,883 +1.9%
Rest of World 3,262 +5.7% 9,431 +3.1% of which China 762 +2.6% 2,087 -1.5%
US sales were €8,603 million and increased by 23.9%. The growth was driven by Immunology (Dupixent and Kevzara), pharma launches, and insulins with vaccines decreasing by 6.8% from lower influenza and Beyfortus sales partly offset by newly acquired Heplisav-B.
Europe sales were €2,579 million and decreased by 0.9%. The slight decrease was driven by influenza vaccines and legacy medicines, only partly offset by Dupixent and pharma launches.
Rest of World sales were €3,262 million and increased by 5.7%. The growth was driven by Dupixent and launches, including Beyfortus. A decrease in legacy medicines offset growth in insulins. Vaccines overall was relatively stable with Beyfortus offsetting a decrease in influenza vaccines. China sales were €762 million and increased by 2.6% in a market growing at about the same rate. Sales growth was driven by Sarclisa, Dupixent, and insulins with vaccines decreasing, mainly the polio/pertussis/ hib primary vaccines due to the decline in childbirths.
Business operating income
In Q3 2026, business operating income (BOI) was €5,430 million and increased by 19.7% (22.2% at actual exchange rates) from €4,445 million in Q3 2025. The ratio of BOI to net sales was 37.4% and increased by 1.7pp (37.6% at actual exchange rates, up by 1.9pp). The increase was mainly driven by growth in business gross profit and operating leverage partly offset by the increase in other operating expenses from higher profit sharing to Sanofi’s collaboration partner Regeneron. In YTD 2026, BOI was €11,688 million and increased by 21.1% (19.2% at actual exchange rates) from €9,808 million in YTD 2025. The ratio of BOI to net sales was 31.9% and increased by 1.6pp (32.0% at actual exchange rates, up by 1.7pp).
Business development
In September, Sanofi and Cheplapharm announced the intention to create a new strategic partnership in mature medicines under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014. The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027, followed by the transfer of the sites, subject to information and consultation procedures with employee representatives, regulatory approvals and customary closing conditions. The transaction is expected to be fully completed by the third quarter of 2027. The medicines being divested from Sanofi include Lovenox/Clexane (enoxaparin), excluding in the US. Lovenox/Clexane had 2025 sales of €822 million. Additional financial details are expected to be provided at a later stage.
In early October, Sanofi and Sanofi’s collaboration partner Regeneron Pharmaceuticals, Inc. announced an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the alliance. Under the expanded license and collaboration agreement, the companies intend to co-develop and co-market four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL13), interleukin-4 (IL4), interleukin-4 receptor alpha (IL4Rα), and an IL4xIL13 bispecific. The IL13 antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis, and the other three molecules are expected to enter clinical studies in 2027. Regeneron will also have the option to include in the collaboration Sanofi’s lunsekimig, exercisable upon completion of its phase 3 studies for chronic obstructive pulmonary disease. Regeneron will receive an upfront payment of $1 billion from Sanofi, with the potential for development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercial costs for the new programmes and will split future profits from these potential new medicines 50:50 on a global basis. Regeneron will lead research and development activities, and Sanofi will lead global commercial efforts. The existing profit-sharing agreement on Dupixent and Kevzara will not change.
SANOFI PRESS RELEASE Q3 2026 2
Financial calendar
Q4 2026 results Thursday, January 28, 2027
Q1 2027 results Friday, April 23, 2027
Q2 2027 results Thursday, July 29, 2027
Q3 2027 results Thursday, 28 October 2027
Biopharma segment
Pharma
Comments on sales performance are provided for all launch medicines and established medicines with sales of minimum €100 million per quarter.
Launches
Recent pharma launches include the medicines ALTUVIIIO, Nexviazyme/Nexviadyme, Ayvakit, Sarclisa, Rezurock, Cablivi, Xenpozyme, Tzield/Teizeild, Wayrilz, Qfitlia, Myqorzo, Anxu, and Redemplo. Individual sales comments are provided in the respective disease area sections while the combined performance of launches is set out in the table below:
Net sales
(€ million) Q3 2026 Change at CER YTD 2026 Change at CER
Total 1,390 +31.4% 3,866 +42.3%
Immunology
Net sales
(€ million) Q3 2026 Change at CER YTD 2026 Change at CER
Dupixent 5,687 +34.8% 15,011 +34.5%
Kevzara 222 +67.9% 523 +42.3%
Dupixent (atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD), bullous pemphigoid, and allergic fungal rhinosinusitis (AFRS)) sales were €5,687 million and increased by 34.8%. Global sales continued to be driven by strong demand growth in each of the up to nine approved indications, mainly from greater use of advanced medicines in each disease. US sales were €4,376 million and increased by 40.2%, primarily driven by strong demand, and by an extended benefit from operational improvements which resulted in favourable gross-to-net price adjustments. In Europe, sales were €588 million and increased by 16.1%, reflecting growth across reimbursed indications and continued growth in the larger markets, including Germany, France, and the UK. In Rest of World, sales were €723 million and increased by 22.6%, mainly driven by Japan, Canada, Brazil, and China.
Kevzara (rheumatoid arthritis, other rheumatological indications) sales were €222 million and increased by 67.9%, mainly driven by increased use in rheumatoid arthritis and polymyalgia rheumatica. US remained the biggest market (€167 million, +87.4%).
Rare diseases
Net sales
(€ million) Q3 2026 Change at CER YTD 2026 Change at CER
ALTUVIIIO 408 +37.8% 1,082 +34.2%
Fabrazyme 260 +6.2% 783 +4.7%
Nexviazyme/Nexviadyme 211 +4.0% 637 +10.9%
Ayvakit 203 +46.0% 570 +329.2%
Cerezyme 173 +6.2% 525 +0.8%
Alprolix 172 +13.4% 454 +3.3%
Myozyme/Lumizyme 105 -15.6% 325 -17.4%
Cablivi 70 +6.1% 223 +12.9%
Xenpozyme 63 +8.8% 190 +15.0%
Wayrilz 19 +1800.0% 46 +4600.0%
Qfitlia 8 +75.0% 20 +300.0%
Myqorzo 3 —% 6 —%
Anxu 1 —% 1 —%
Redemplo 1 —% 1 —%
ALTUVIIIO (coagulation disorder, factor VIII) sales were €408 million of which 85% was in the US. Growth continued to be driven by patients switching from legacy, shorter half-life factor medicines, and some patients from non-factor medicines. Rest of World sales were €63 million and increased by 40.4% as supply sales adjusted to Sanofi’s collaboration partner Sobi. The factor
SANOFI PRESS RELEASE Q3 2026 3
VIII medicine franchise (ALTUVIIIO and Eloctate) sales were €453 million and increased by 21.3%. Eloctate contributed €45 million and decreased by 41.6%, driven by the absence of supplies to Sanofi’s collaboration partner Sobi. Fabrazyme (Fabry disease) sales were €260 million and increased by 6.2%, driven by the US (+8.9%) from more patients and higher price, partly offset by slower growth in Europe (+1.6%, to €63 million).
Nexviazyme/Nexviadyme (Pompe disease) sales were €211 million and increased by 4.0%, driven by the US (+14.3%) and Rest of World (+10.7%), partly offset by Europe (-12.2%). Across all geographies, patients are switching from Myozyme/Lumizyme. The Pompe disease franchise (Nexviazyme/Nexviadyme and Myozyme/Lumizyme) sales were €316 million (-3.4%). In general, supply constraints reduce growth.
Ayvakit (systemic mastocytosis) sales were €203 million. Sales were mainly split between the US (€178 million) and Europe (€23 million) with continued growth in the number of patients treated and their duration of treatment. Higher government rebates because of the originator Blueprint becoming part of Sanofi continued to impact US sales. On a market pro-forma basis, sales reached $234 million, an increase of 14.4% from $204 million in Q3 2025. Royalty on sales by CStone Pharmaceuticals in China is recorded in other revenues.
Cerezyme (Gaucher disease) sales were €173 million and increased by 6.2%, driven by Rest of World (+21.3%), partly offset by the US (-2.3%) and Europe (-3.6%). The Gaucher disease franchise (Cerezyme and Cerdelga) sales were €268 million and increased by 6.9%.
Alprolix (coagulation disorder, factor IX) sales were €172 million and increased by 13.4%, driven by Rest of World (+27.9%, to €55 million) mainly due to increased supplies to Sanofi’s collaboration partner Sobi. Growth in the US (+7.5%) partly benefited from gross-to-net price adjustments.
Myozyme/Lumizyme (Pompe disease) sales were €105 million and decreased by 15.6% driven by patients switching to Nexviazyme/Nexviadyme and supply constraints.
Cablivi (acquired thrombotic thrombocytopenic purpura) sales were €70 million and increased by 6.1%, driven by the US (+8.6%), mainly from increased patient use. Sales in Europe were €26 million (+4.0%) and in Rest of World €5 million (unchanged). Xenpozyme (acid sphingomyelinase deficiency) sales were €63 million and increased by 8.8%, driven by the US (+17.4%). Wayrilz (immune thrombocytopenia) sales were €19 million, all in the US, following approval in August 2025. Qfitlia (hemophilia A/B) sales were €8 million, of which €7 million in the US, following approval in March 2025. Myqorzo (obstructive hypertrophic cardiomyopathy) sales were €3 million after launch in China during the first quarter. Anxu (myelofibrosis) sales were €1 million after launch in China during the second quarter.
Redemplo (familial chylomicronemia syndrome) sales were €1 million after launch in China during the third quarter.
Other main medicines
Net sales
(€ million) Q3 2026 Change at CER YTD 2026 Change at CER
Lantus 530 +18.5% 1,343 +3.7%
Toujeo 430 +31.2% 1,159 +15.0%
Plavix 206 -10.8% 646 -6.5%
Sarclisa 196 +25.8% 550 +30.4%
Lovenox 174 -12.8% 538 -17.3%
Rezurock 165 +43.0% 461 +25.7%
Praluent 156 +20.5% 473 +19.0%
Thymoglobulin 134 +10.2% 391 +9.0%
Aprovel 103 -1.0% 321 +2.6%
Tzield/Teizeild 42 +127.8% 79 +70.2%
Lantus (diabetes) sales were €530 million and increased by 18.5%. US sales were €293 million and increased by 35.0% primarily driven by favourable gross-to-net price adjustments and supported by market share gains. Sales also continued to benefit from temporary demand from competitor supply disruptions, an effect expected to moderate over time. Combined sales in Europe and Rest of World increased by 2.7%.
Toujeo (diabetes) sales were €430 million and increased by 31.2%, driven mainly by the US (+121.8%) from favourable gross-tonet price adjustments and market share gains. Sales in Rest of World (+19.0%) and Europe (+4.8%) also grew from an increase in market share.
Plavix (antiplatelet, cardiovascular disease) sales were €206 million and decreased by 10.8%, driven by lower Rest of World sales (majority of sales, €185 million, -11.0%).
Sarclisa (multiple myeloma) sales were €196 million and increased by 25.8%, driven by high growth in Rest of World (+33.3%, to €64 million) and Europe (+28.3%, to €59 million). Sales in the US were €73 million (+18.0%). Globally, growth was supported by increased use in earlier lines of treatment, including front-line transplant-ineligible patients in combination with standard-ofcare chemotherapy combinations. The ongoing launch of the new subcutaneous formulation also contributed to growth. Lovenox (anticoagulant, cardiovascular disease) sales were €174 million and decreased by 12.8%, from lower sales in Europe (-17.8%, to €89 million) and Rest of World (-9.1%, to €82 million), driven by the impact of biosimilar competitors.
SANOFI PRESS RELEASE Q3 2026 4
Rezurock (chronic graft‑versus‑host disease) sales were €165 million and increased by 43.0% from strong growth in Rest of World (+40.0%, to €21 million). Sales in Europe were €19 million and in the US €125 million (+24.0%), supported by price. Praluent (primary hypercholesterolemia, mixed dyslipidemia) sales were €156 million and increased by 20.5% from higher sales in Europe (+24.5%, to €133 million).
Thymoglobulin (rejection prevention in kidney transplantation) sales were €134 million and increased by 10.2%, mainly driven by Rest of World (+13.5%, to €46 million).
Aprovel (antihypertension, cardiovascular disease) sales were €103 million and decreased by 1.0%, with sales coming mainly from Rest of World (€84 million, -1.2%).
Tzield/Teizeild (diabetes) sales were €42 million and increased by 127.8%. Sales in the US were €39 million and €3 million in Europe where launch is underway in Germany. A total of almost 1,100 patients have now received treatment with Tzield/Teizeild.
Vaccines
Net sales
(€ million) Q3 2026 Change at CER YTD 2026 Change at CER
Influenza, COVID-19 1,256 -18.8% 1,377 -21.7%
Polio/pertussis/hib primary and boosters, incl. Heplisav-B 823 +24.9% 2,187 +9.9%
Beyfortus 631 -15.4% 1,023 -6.1%
Meningitis, travel, and endemic 476 +4.2% 1,041 -0.5%
Total 3,185 -6.6% 5,628 -4.3 %
Vaccines sales were €3,185 million and decreased by 6.6%, mainly driven by phasing of influenza and lower Beyfortus US sales. Influenza, COVID-19 vaccines sales were €1,256 million and decreased by 18.8%, mainly due to phasing of seasonal deliveries in the Northern Hemisphere with a higher proportion in the fourth quarter compared to 2025.
Polio/pertussis/hib primary and booster vaccines, including Heplisav-B sales were €823 million and increased by 24.9%. Sales in the US (€353 million, +69.8%) continued to benefit from newly acquired Heplisav-B while sales in Rest of World (€347 million, +0.3%) were impacted by fewer childbirths, primarily in China.
Beyfortus sales were €631 million and decreased by 15.4%, driven by the US (€240 million, -39.3%), including a lower central order from the Centers for Disease Control and Prevention. This was partly offset by Europe (€266 million, +1.9%) and Rest of World (€125 million, +38.2%) benefiting from the expanded geographical availability as Beyfortus is now protecting babies in more than 50 countries.
Meningitis, travel, and endemic vaccines sales were €476 million and increased by 4.2% from higher sales in all geographies.
Pipeline update
Sanofi has 61 projects in a pipeline across three main areas (Immunology, Rare diseases, and Vaccines) and selectively in the disease areas of Neurology and Oncology, including 36 potential new medicines and vaccines. The following section highlights significant developments in the late- and mid-stage pipeline since the prior results press release.
Highlights
Abbreviations used in the table below are explained in the body text:
The list of all pipeline changes is available from the Q3 2026 results investor presentation, pipeline appendix.
Immunology
Tzield/Teizeild (teplizumab)
The European Medicines Agency (EMA) accepted Teizeild for regulatory review to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged one to seven years diagnosed with stage 2 T1D. Teizeild is already approved for this indication in adults and children aged eight years and older.
lunsekimig (IL13xTSLP Nanobody® VHH)
At the European Respiratory Society Congress 2026 in Barcelona, Spain, positive phase 2 data from two separate studies showed that lunsekimig, targeting thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL13), led to clinically meaningful improvements in patients with asthma and CRSwNP.
The AIRCULES phase 2b dose-ranging study (clinical study identifier: NCT06102005) evaluated the efficacy, safety, and tolerability of lunsekimig in addition to standard of care therapy over 48 weeks in adult patients with moderate-to-severe asthma who had one or more exacerbations in the preceding year, compared with placebo. Lunsekimig 300 mg every four weeks (Q4W) achieved a statistically significant and clinically meaningful reduction in the annual asthma exacerbation rate SANOFI PRESS RELEASE Q3 2026 5 over 48 weeks compared to placebo, regardless of biomarker status, meeting the study’s primary objective. The study also met the key secondary endpoint, demonstrating statistically significant and clinically meaningful improvements in lung function at week 48, as measured by pre-bronchodilator forced expiratory volume in 1 second compared to placebo, which was observed as early as week 4 and sustained through week 48. In addition, patients reported improvements in scores for the asthma control questionnaire.
The DUET phase 2a proof-of-concept study (clinical study identifier: NCT06454240) evaluated the efficacy, safety, and tolerability of lunsekimig 300 mg Q4W in addition to standard-of-care therapy, in adult patients with CRSwNP compared with placebo at week 24. Lunsekimig demonstrated statistically significant and clinically meaningful improvements across all primary and key secondary endpoints.
In both studies, lunsekimig was well-tolerated.
Rare diseases
Ayvakit (avapritinib)
The US FDA approved a label update for Ayvakit including a 50 mg daily dose option in adults with indolent systemic mastocytosis (ISM), for use as clinically indicated after at least six months of treatment at 25 mg daily, which remains the recommended starting dose. ISM is defined by a broad spectrum of disease activity that varies by patient, highlighting the importance of providing flexibility to healthcare providers to address these diverse medical needs. This label update was based on observed data for Ayvakit 50 mg from the long-term, open-label extension portion of the PIONEER clinical trial (clinical study identifier: NCT03731260).
Vaccines
MenQuadfi (meningococcal disease)
The EU approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi was previously approved in the EU for use in individuals aged 12 months and older. Invasive meningococcal disease is a life-threatening bacterial infection that can progress rapidly, with patients potentially deteriorating from the onset of symptoms to death within 24 hours. Infants are among the populations at highest risk for invasive meningococcal disease, facing high rates of mortality and severe long-term complications. Although serogroup A is now rarely reported in the EU, serogroups C, W, and Y remain responsible for a significant share of invasive meningococcal disease cases. Beyfortus (nirsevimab)
The Chinese National Medical Products Administration granted a priority review to Beyfortus for the regulatory submission to extend the indication to children up to 24 months of age during their second respiratory syncytial virus (RSV) season. Beyfortus is currently approved for the prevention of RSV lower respiratory tract infection in neonates and infants entering or during their first RSV season.
SP0087 (rabies)
The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for SP0087 for pre- and postexposure prophylaxis against rabies in all age groups. This next-generation vaccine is highly purified, free from human and animal-origin materials, with enhanced thermostability and longer shelf-life.
SP0289 (influenza H5 pandemic)
The CHMP granted PRIME eligibility to the second generation structurally designed mRNA influenza H5 pandemic vaccine. This pandemic preparedness vaccine is intended for prevention of influenza in case of an officially declared pandemic. The CHMP acknowledged the vaccine's potential to address unmet medical need, noting the mRNA platform enables rapid manufacturing and adaptation to emerging virus variants or novel pandemic strains.
Acting for nature: reducing dependencies, building resilience
Biodiversity is a key focus area in the efforts to limit the impact on nature and reduce to a minimum the use of natural resources. Sanofi has completed a nature-related risk and dependency analysis across its operations and value chain. The analysis identified four critical nature-based commodities: horseshoe crab blood, palm oil, cattle, and pig derivatives. Although the projected cost impacts are financially immaterial, Sanofi is proactively strengthening its long-term resilience through targeted adaptation measures.
Horseshoe crab blood is essential for testing the safety of injectable medicines and vaccines, as required by regulators. Sanofi is accelerating its transition to synthetic alternatives and has an action plan with the following targets to be achieved by the end of 2030: (1) 70% of endotoxin tests performed without horseshoe crab reagents in all Sanofi quality control laboratories; (2) All new launches submitted with synthetic method.
This plan reinforces Sanofi's commitment to reducing its impact on nature, while safeguarding uninterrupted access to medicines for patients worldwide.
ESG ratings
Sanofi’s current ESG rankings:
SANOFI PRESS RELEASE Q3 2026 8
Q3 and YTD 2026 financial results
Business net income1
Net sales were €14,444 million in Q3 2026 and increased by 16.2% (14.3% at CER) from €12,434 million in Q3 2025. In YTD 2026, net sales were €36,550 million and increased by 13.1% (15.2% at CER) from €32,323 million in YTD 2025. Other revenues were €789 million in Q3 2026 and increased by 7.2% (5.6% at CER) from €736 million in Q3 2025. VaxServe sales of non-Sanofi vaccines were €494 million and increased by 2.1% (0.4% at CER). In addition, other revenues included sales of Opella consumer-health products in certain markets (€149 million), manufacturing services and other (€75 million), royalties (€49 million), and supply sales to Opella (€22 million). In YTD 2026, other revenues were €2,227 million and increased by 1.8% (3.7% at CER) from €2,188 million in YTD 2025. VaxServe sales of non-Sanofi vaccines were €1,240 million and decreased by 6.5% (3.4% at CER). In addition, other revenues included sales of Opella consumer-health products in certain markets (€419 million), manufacturing services and other (€346 million), royalties (€140 million), and supply sales to Opella (€82 million). Business gross profit was €11,698 million in Q3 2026 and increased by 19.2% (17.2% at CER) from €9,815 million in Q3 2025. The business gross margin was 81.0% and increased by 2.1pp (81.0% at CER, up by 2.1pp). The margin improvement in Q3 was driven by improved product mix, including a higher proportion of specialty care and rare disease medicines and an element of benefit from favourable gross-to-net price adjustments. In YTD 2026, business gross profit was €29,297 million and increased by 15.9% (18.3% at CER) from €25,275 million in YTD 2025. The business gross margin was 80.2% and increased by 2.0pp (80.3% at CER, up by 2.1pp).
Research and Development expenses were €1,849 million in Q3 2026 and increased by 0.8% (down by 0.1% at CER) from €1,834 million in Q3 2025, mainly reflecting past project terminations in Vaccines. The ratio of R&D to net sales was 12.8% and decreased by 1.9pp (12.9% at CER, down by 1.8pp). In YTD 2026, R&D expenses were €5,829 million and increased by 5.0% (6.6% at CER) from €5,551 million in YTD 2025. The ratio of R&D to net sales was 15.9% and decreased by 1.3pp (15.9% at CER, down by 1.3pp).
Selling and general expenses were €2,309 million in Q3 2026 and increased by 0.8% (down by 0.9% at CER) from €2,291 million in Q3 2025, reflecting cost discipline. The ratio of expenses to net sales was 16.0% and decreased by 2.4pp (16.0% at CER, down by 2.4pp). In YTD 2026, SG&A expenses were €7,101 million and increased by 4.5% (6.5% at CER) from €6,797 million in YTD 2025. The ratio of SG&A to net sales was 19.4% and decreased by 1.6pp (19.4% at CER, down by 1.6pp). Other operating income net of expenses was -€2,168 million in Q3 2026 and increased by 66.4% (64.4% at CER) from -€1,303 million in Q3 2025. In YTD 2026, other operating income net of expenses was -€4,804 million and increased by 48.0% (53.9% at CER) from -€3,246 million in YTD 2025. Details are available from the table below:
(€ million) Q3 2026 Q3 2025 YTD 2026 YTD 2025
Net gains/(losses) on disposals of operating assets or businesses 14 85 255 428 of which medicine divestments/portfolio streamlining (3) 85 225 419
(ii) Additional profit share for development cost from Regeneron 11 293 605 787
(iii) Selling expense reimbursements to Regeneron (180) (175) (516) (521)
Other (153) (231) (361) (380)
Total other operating expenses (2,552) (1,600) (5,988) (4,076)
Other operating income/(expense), net (2,168) (1,303) (4,804) (3,246)
Share of profit from investments accounted for using the equity method was €62 million in Q3 2026 and unchanged from €62 million in Q3 2025 and mainly included the share of profit related to Vaxelis. EUROAPI and Opella are included only in the IFRS accounts (please see the net income reconciliation below). In YTD 2026, the share of profit from investments accounted for using the equity method was €136 million compared to €139 million in YTD 2025 and mainly included the share of profit related to Vaxelis.
Business operating income was €5,430 million in Q3 2026 and increased by 22.2% (19.7% at CER) from €4,445 million in Q3 2025. The ratio of BOI to net sales was 37.6% and increased by 1.9pp (37.4% at CER, up by 1.7pp). The increase was mainly driven by growth in business gross profit and operating leverage partly offset by the increase in other operating expenses from higher profit sharing to Sanofi’s collaboration partner Regeneron. In YTD 2026, BOI was €11,688 million and increased by 19.2% (21.1% at CER) from €9,808 million in YTD 2025. The ratio of BOI to net sales was 32.0% and increased by 1.7pp (31.9% at CER, up by 1.6pp).
Net financial expenses were €101 million in Q3 2026 compared to €64 million in Q3 2025, reflecting higher net debt in the quarter. In YTD 2026, net financial expenses were €283 million compared to €191 million in YTD 2025, similarly reflecting higher net debt.
SANOFI PRESS RELEASE Q3 2026 9
1 See Appendix 3 for the IFRS consolidated income statement, see Appendix 8 for definitions of non-IFRS financial measures, and see Appendix 4 for a reconciliation of IFRS net income to business net income.
The effective tax rate was 20.4% in Q3 2026 and increased from 19.3% in Q3 2025. Generally, the effective tax rate will fluctuate from quarter to quarter. In YTD 2026, the effective tax rate was 21.1% and increased from 20.2% in YTD 2025. Following decisions made on the pipeline, Sanofi now anticipates an effective tax rate in 2026 of c.21%.
Business net income was €4,255 million in Q3 2026 and increased by 20.0% (+17.6% at CER) from €3,547 million in Q3 2025. The ratio of business net income to net sales was 29.5% and increased by 1.0pp (29.3% at CER, up by 0.8pp). In YTD 2026, business net income was €9,020 million and increased by 17.2% (19.1% at CER) from €7,699 million in YTD 2025. The ratio of business net income to net sales was 24.7% and increased by 0.9pp (24.6% at CER, up by 0.8pp).
Business earnings per share (business EPS) was €3.55 in Q3 2026 and increased by 22.0% (19.6% at CER) from €2.91 in Q3 2025. The average number of shares outstanding was 1,200.0 million in Q3 2026 compared to 1,218.1 million in Q3 2025. In YTD 2026, business EPS was €7.52 and increased by 19.4% (21.3% at CER) from €6.30 in YTD 2025. The average number of shares outstanding was 1,200.2 million in YTD 2026 compared to 1,223.0 million in YTD 2025.
Opella
On April 30, 2025, Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader. Sanofi retained a significant shareholding in Opella through a 48.2% equity interest in OPAL JV Co, which indirectly holds 100% of Opella. Bpifrance owns 1.8% and CD&R the remaining 50.0%. The transaction was completed on the terms previously disclosed, and Sanofi received net cash proceeds of €10.4 billion in 2025. To aid the ongoing assessment of the value of Sanofi’s Opella stake, Opella’s summary financials are disclosed at Q2/H1 and Q4/FY financial results.
Reconciliation of IFRS net income to business net income (see Appendix 4)
In YTD 2026, IFRS net income was €4,979 million. The main items excluded from business net income were:
Net income from discontinued operations, amounting to €26 million.
Amortisation expense of €1,643 million. Of this, €1,579 million related to intangible assets measured at their acquisition-date fair values (Ayvakit €442 million, Bioverativ €430 million, Tzield €157 million, Ablynx €123 million, Rezurock €114 million, Beyfortus €88 million, Heplisav-B €63 million, and Aventis €3 million), and €64 million related to intangible assets from other acquisitions and initially measured at acquisition cost (licenses/products). These items had no cash impact.
Impairment expense of €1,018 million, mainly comprising a €952 million impairment loss related to the amlitelimab intangible asset booked in Q2 2026.
The €307 million impact of the unwinding of the step-up of inventories remeasured at their acquisition-date fair values, which relates to the Blueprint and Dynavax acquisitions and is reported within cost of sales in the IFRS consolidated income statement.
Restructuring costs and similar items of €648 million, mainly related to redundancy plans of €308 million, expenses related to assets of €225 million, and integration and acquisition costs of €91 million (including Blueprint and Dynavax).
Other gains and losses, and litigation, of €382 million, mainly related to ongoing major litigations.
A financial expense of €191 million related to the re-measurement of the liability related to royalties on Beyfortus US sales.
A €566 million tax effect arising from the items listed above, mainly comprising €290 million of deferred taxes generated by amortisation and impairment of intangible assets, and €105 million associated with restructuring costs and similar items.
Other items included Sanofi’s share of losses from investments accounted for using the equity method, relating to its associates EUROAPI and OPAL JV Co (Opella).
Cash flow
In YTD 2026, after a decrease in net working capital of €801 million and capital expenditures of €1,512 million, free cash flow before restructuring, acquisitions, and disposals amounted to €7,771 million. After cash outflows of €599 million related to restructuring and similar items and of €674 million related to acquisitions1, and proceeds from disposals1 of €495 million, free cash flow2 was €6,993 million.
Net debt
Net debt increased by €1,213 million. Free cash flow of €6,993 million was more than offset by: the acquisition of Dynavax for €1,645 million; the share buyback of €1,013 million; the dividend payout of €4,923 million; the net cash outflow from the Opella transaction of €225 million; a negative foreign exchange impact on net debt of €219 million; and other negative items of €181 million. As a result, net debt increased from €10,988 million on January 1, 2026 (after the adjustment from the IFRS 9 amendment at the start of the period) to €12,201 million on September 30, 2026 (net of €5,966 million in cash and cash equivalents).